Future of Abbott Laboratories | Quantumrun

Future of Abbott Laboratories

Abbott Laboratories is one of the world's leaders in the healthcare industry. The company has operated since 1888, since its founding by Chicago physician Wallace Calvin Abbot. Abbott Laboratories has since expanded and started selling medical devices, research-based medications, nutritional supplements, and diagnostics. In 2013, the multinational founded Abbvie to handle all the research-based drugs operations. Today, Abbott Laboratories is headquartered in Lake Bluff, Illinois.

Home Country: 
United States
Industry: 
Medical Products and Equipment
Industry vulnerability to disruption: 

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

Total patents held: 
6 254
Number of patents field last year: 
45
Ranking List: 
13
Ranking List: 
2017 Quantumrun Global 1000
10
Ranking List: 
2017 Quantumrun US 500
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.31
Market country 
Brazil
Revenue from country 
0.33
Prod/Serv name revenue: 
Prod/Serv name: 
Established pharmaceutical
Prod/Serv revenue: 
3720000000
Prod/Serv name: 
Nutritional
Prod/Serv revenue: 
6975000000
Prod/Serv name: 
Diagnostic
Prod/Serv revenue: 
4646000000
Founded: 
1888
Company Name: 
Abbott Laboratories
Sector: 
Revenue: 
20853000000
3y average revenue: 
20501666667
Operating expenses: 
17668000000
3y average expenses: 
17618000000
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
75000
Domestic employee count: 
39313
Number of domestic locations: 
10
Funds in reserve: 
18620000000
Investment into R&D: 
550000000
create term: 
#13 | 2017 Quantumrun Global 1000
#10 | 2017 Quantumrun US 500

Abbott Laboratories is one of the world's leaders in the healthcare industry. The company has operated since 1888, since its founding by Chicago physician Wallace Calvin Abbot. Abbott Laboratories has since expanded and started selling medical devices, research-based medications, nutritional supplements, and diagnostics. In 2013, the multinational founded Abbvie to handle all the research-based drugs operations. Today, Abbott Laboratories is headquartered in Lake Bluff, Illinois.

Home country:
United States
Sector:
Health Care
Industry:
Medical Products and Equipment
Founded:
1888
Global employee count:
75,000
Domestic employee count:
39,313

Financial Health

Revenue
$20,853,000,000 USD
3y average revenue
$20,501,666,667 USD
Operating expenses
$17,668,000,000 USD
3y average expenses
$17,618,000,000 USD
Funds in reserve
$18,620,000,000 USD
#1 Market country
United States
% of revenue from country #1
0.31%
#2 Market country
Brazil
% of revenue from country #2
0.33%

Asset Performance

#1 Product/Service/Dept. name
Established pharmaceutical
#1 Product/Service revenue
$3,720,000,000 USD
#2 Product/Service/Dept. name
Nutritional
#2 Product/Service revenue
$6,975,000,000 USD
#3 Product/Service/Dept. name
Diagnostic
#3 Product/Service revenue
$4,646,000,000 USD

Innovation assets and Pipeline

Investment into R&D
$550,000,000 USD
Total patents held
6,254
Number of patents field last year
45
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.